Ironwood Pharmaceuticals And Forest Laboratories Announce Presentation Of Linaclotide Phase 2b Chronic Constipation Study Results Ironwood Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories, Inc. (NYSE: FRX) today announced the presentation of data from a Phase 2b randomized, double-blind, placebo-controlled study assessing the safety and efficacy of linaclotide in patients with chronic constipation (CC). Analysis of these data indicate that linaclotide met its primary endpoint.
Source: www.medicalnewstoday.comDenosumab Osteoporosis Study Meets Primary And All Secondary Bone Mineral Density Endpoints In Alendronate (FOSAMAX(R)) Transition Study Amgen (NASDAQ: AMGN) announced findings from a head-to-head, double blind trial comparing the effects of denosumab in post-menopausal women with low bone mass transitioned from weekly alendronate (FOSAMAX(R)) versus continued alendronate therapy on bone mineral density (BMD). The study demonstrated superior results for the primary and all secondary endpoints.
Source: www.medicalnewstoday.comHeroes Of Emergency Medicine: Drs. Marianne Gausche-Hill And Robert Hockberger The American College of Emergency Physicians (ACEP) has announced it has recognized Marianne Gausche-Hill, M.D., FACEP, and Robert Hockberger, M.D., FACEP, as Heroes of Emergency
Medicine, an honor the organization bestows upon emergency physicians who have made significant contributions to emergency
medicine, their communities and their patients.
Source: www.medicalnewstoday.comResearcher Strives For Watershed Moment According to the World
Health Organization, water scarcity affects four out of every 10 people around the world and population growth, urbanization and increased domestic and industrial water use are making the problem worse. By examining the relationship between global warming and pollution, a researcher at The University of Western Ontario hopes to help protect future water resources.
Source: www.medicalnewstoday.comWhy Do Astronauts Suffer From Space Sickness? Centrifuging astronauts for a lengthy period provided researcher Suzanne Nooij with better insight into how space sickness develops, the nausea and disorientation experienced by many astronauts. Nooij defended her PhD theses on this subject at Delft University of Technology (TU Delft, The Netherlands) on Tuesday 20 May.Gravity plays a major role in our spatial orientation.
Source: www.medicalnewstoday.com$11.6M NIH Grant To Study Novel Mechanisms Of Heart Failure Received By Jefferson Scientists at Jefferson Medical College have received a five-year, $11.6 million grant from the National Heart, Lung and Blood Institute to study molecular mechanisms of cardiac injury that lead to heart failure and potential repair processes that occur in the adult failing heart. This project aims to find data that can be translated into novel therapeutic strategies to improve the failing heart.
Source: www.medicalnewstoday.comData Show Rufinamide, An Investigational Adjunctive Treatment For Lennox- Gastaut Syndrome, Reduced Drop Attacks By More Than 40% Eisai Corporation of North America announced the publication of a placebo-controlled study in Neurology that found patients with Lennox-Gastaut syndrome (LGS) treated with the investigational antiepileptic agent rufinamide as adjunctive therapy experienced more than 40% fewer drop attacks than patients who received placebo (increase of 1.4%).
Source: www.medicalnewstoday.comTelik Announces Initiation Of Two Phase 2 Randomized TELINTRA Studies Telik, Inc. (Nasdaq: TELK), announced it has initiated two Phase 2 TELINTRA(R) studies -- one with TELINTRA tablets in myelodysplastic syndrome, or MDS, and a second with TELINTRA tablets in cancer patients at risk for chemotherapy-induced neutropenia, or CIN.
Source: www.medicalnewstoday.comLabels: No Prescription, Online Pharmacy
# posted by Network @ 12:00 PM
